Achilles Therapeutics plc ACHL
Set alert
1.48 0.00 0.00%
At close · Mar 20
1.48 Day range 1.48
52-week range unavailable
- YTD
- +29.82%
- 1 year
- +14.73%
- Open
- 1.48
- Prev close
- 1.48
- Mkt cap
- 48.70M
- Vol
- 1.20M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.48
- High
- 1.48
- Forward P/E
- -0.61
- Beta
- 1.34
- Short ratio
- 1.69
- Inst. own
- 59.30%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2024
- 50-d avg
- 1.02
- 200-d avg
- 0.91881
- 1y target
- 0.00
2Y chart
Events in this range
- May 11, 2023Rating: Chardan Capital · Buy → Buy
- Aug 7, 2023Rating: Chardan Capital · Buy → Buy
- Dec 14, 2023Downgrade: B of A Securities · Buy → Underperform
- Apr 4, 2024Earnings: —; estimate 0; surprise —%
- Apr 5, 2024Downgrade: Piper Sandler · Overweight → Neutral
- Apr 5, 2024Rating: Chardan Capital · Buy → Buy
- May 8, 2024Earnings: -0.3; estimate -0.46; surprise 34.78%
- May 8, 2024Earnings: —; estimate -0.46; surprise —%
- Aug 14, 2024Earnings: —; estimate -0.41; surprise —%
- Aug 14, 2024Earnings: -0.41; estimate -0.41; surprise 0%
- Nov 14, 2024Earnings: -0.48; estimate -0.41; surprise -17.07%
Signals (98)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Mar 18, 2025 | 1 year ago |
| RSI: Overbought | Mar 13, 2025 | 1 year ago |
| RSI: Overbought | Feb 26, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 24, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 4, 2025 | 1 year ago |
| RSI: Overbought | Feb 4, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 17, 2025 | 1 year ago |
| RSI: Overbought | Dec 30, 2024 | 1 year ago |
| SMA: Bullish | Dec 24, 2024 | 1 year ago |
| MACD: Buy Signal | Dec 24, 2024 | 1 year ago |
| RSI: Overbought | Dec 24, 2024 | 1 year ago |
| RSI: Oversold | Dec 17, 2024 | 1 year ago |
| SMA: Bearish | Dec 11, 2024 | 1 year ago |
| MACD: Sell Signal | Nov 11, 2024 | 1 year ago |
| MACD: Buy Signal | Nov 7, 2024 | 1 year ago |
| MACD: Sell Signal | Oct 10, 2024 | 2 years ago |
| RSI: Overbought | Oct 3, 2024 | 2 years ago |
| RSI: Overbought | Sep 26, 2024 | 2 years ago |
| SMA: Bullish | Sep 19, 2024 | 2 years ago |
| SMA: Bullish | Sep 19, 2024 | 2 years ago |
| RSI: Overbought | Sep 19, 2024 | 2 years ago |
| MACD: Buy Signal | Sep 6, 2024 | 2 years ago |
| MACD: Sell Signal | Sep 3, 2024 | 2 years ago |
| MACD: Buy Signal | Aug 26, 2024 | 2 years ago |
| MACD: Sell Signal | Aug 1, 2024 | 2 years ago |
| MACD: Buy Signal | Jul 31, 2024 | 2 years ago |
| MACD: Sell Signal | Jul 30, 2024 | 2 years ago |
| MACD: Buy Signal | Jul 11, 2024 | 2 years ago |
| SMA: Bearish | Jun 26, 2024 | 2 years ago |
| SMA: Bullish | Jun 25, 2024 | 2 years ago |
| SMA: Bearish | Jun 20, 2024 | 2 years ago |
| MACD: Sell Signal | Jun 7, 2024 | 2 years ago |
| SMA: Bearish | Jun 6, 2024 | 2 years ago |
| SMA: Bullish | Jun 5, 2024 | 2 years ago |
| SMA: Bullish | Jun 5, 2024 | 2 years ago |
| SMA: Bearish | May 31, 2024 | 2 years ago |
| SMA: Bearish | May 31, 2024 | 2 years ago |
| SMA: Bullish | May 30, 2024 | 2 years ago |
| SMA: Bullish | May 30, 2024 | 2 years ago |
| SMA: Bearish | May 22, 2024 | 2 years ago |
| SMA: Bullish | May 21, 2024 | 2 years ago |
| SMA: Bearish | May 20, 2024 | 2 years ago |
| SMA: Bullish | May 17, 2024 | 2 years ago |
| MACD: Buy Signal | Apr 29, 2024 | 2 years ago |
| RSI: Oversold | Apr 25, 2024 | 2 years ago |
| RSI: Oversold | Apr 19, 2024 | 2 years ago |
| RSI: Oversold | Apr 16, 2024 | 2 years ago |
| RSI: Oversold | Apr 5, 2024 | 2 years ago |
| SMA: Bearish | Apr 4, 2024 | 2 years ago |
| SMA: Bearish | Apr 4, 2024 | 2 years ago |
| MACD: Sell Signal | Mar 6, 2024 | 2 years ago |
| RSI: Overbought | Feb 21, 2024 | 2 years ago |
| MACD: Buy Signal | Feb 14, 2024 | 2 years ago |
| MACD: Sell Signal | Feb 9, 2024 | 2 years ago |
| SMA: Bullish | Jan 31, 2024 | 2 years ago |
| SMA: Bearish | Jan 30, 2024 | 2 years ago |
| SMA: Bullish | Jan 25, 2024 | 2 years ago |
| MACD: Buy Signal | Jan 24, 2024 | 2 years ago |
| SMA: Bullish | Jan 23, 2024 | 2 years ago |
| SMA: Bearish | Jan 17, 2024 | 2 years ago |
| MACD: Sell Signal | Jan 17, 2024 | 2 years ago |
| SMA: Bearish | Jan 11, 2024 | 2 years ago |
| SMA: Bullish | Jan 8, 2024 | 2 years ago |
| MACD: Buy Signal | Jan 8, 2024 | 2 years ago |
| SMA: Bearish | Jan 3, 2024 | 2 years ago |
| MACD: Sell Signal | Jan 3, 2024 | 2 years ago |
| MACD: Buy Signal | Dec 29, 2023 | 2 years ago |
| SMA: Bullish | Dec 27, 2023 | 2 years ago |
| MACD: Sell Signal | Dec 19, 2023 | 2 years ago |
| SMA: Bearish | Dec 18, 2023 | 2 years ago |
| SMA: Bullish | Dec 7, 2023 | 2 years ago |
| MACD: Buy Signal | Nov 27, 2023 | 2 years ago |
| SMA: Bearish | Nov 7, 2023 | 2 years ago |
| SMA: Bullish | Nov 6, 2023 | 2 years ago |
| MACD: Sell Signal | Oct 31, 2023 | 3 years ago |
| SMA: Bearish | Oct 26, 2023 | 3 years ago |
| SMA: Bullish | Oct 25, 2023 | 3 years ago |
| SMA: Bearish | Oct 23, 2023 | 3 years ago |
| SMA: Bullish | Oct 19, 2023 | 3 years ago |
| MACD: Buy Signal | Oct 13, 2023 | 3 years ago |
| MACD: Sell Signal | Oct 5, 2023 | 3 years ago |
| MACD: Buy Signal | Sep 18, 2023 | 3 years ago |
| MACD: Sell Signal | Sep 7, 2023 | 3 years ago |
| MACD: Buy Signal | Sep 1, 2023 | 3 years ago |
| SMA: Bearish | Aug 11, 2023 | 3 years ago |
| SMA: Bullish | Aug 10, 2023 | 3 years ago |
| SMA: Bearish | Aug 9, 2023 | 3 years ago |
| SMA: Bullish | Aug 7, 2023 | 3 years ago |
| SMA: Bearish | Aug 2, 2023 | 3 years ago |
| MACD: Sell Signal | Jul 31, 2023 | 3 years ago |
| RSI: Overbought | Jul 21, 2023 | 3 years ago |
| RSI: Overbought | Jul 19, 2023 | 3 years ago |
| MACD: Buy Signal | Jul 13, 2023 | 3 years ago |
| SMA: Bullish | Jul 12, 2023 | 3 years ago |
| SMA: Bearish | Jun 30, 2023 | 3 years ago |
| MACD: Sell Signal | Jun 2, 2023 | 3 years ago |
| RSI: Overbought | May 22, 2023 | 3 years ago |
| RSI: Overbought | May 9, 2023 | 3 years ago |
Key statistics
- Market cap
- 48.70M
- Enterprise value
- -46.68M
- Trailing P/E
- 0.00
- Forward P/E
- -0.61
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.33
- EPS (TTM)
- -1.66
- Beta
- 1.34
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -30.14M
- Total cash
- 95.11M
- Total debt
- 4.46M
- Return on equity
- -44.22%
- Shares outstanding
- 41.09M
- Short % of float
- 0.63%
- 50-day average
- 1.02
- 200-day average
- 0.91881
Analyst view
Consensus: buy
Buy
Price target (mean) 0.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate 0.00.
Financials — quick view
ACHL Revenue — quarterly 0
ACHL Net income — quarterly -19.59M
ACHL EPS — quarterly -0.48
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.41 | -0.48 | -0.07 | -17.07% |
| Aug 14, 2024 | Jun 1, 2024 | -0.41 | — | — | — |
| Aug 14, 2024 | Jun 1, 2024 | -0.41 | -0.41 | 0.00 | 0.00% |
| May 8, 2024 | Mar 1, 2024 | -0.46 | -0.30 | +0.16 | +34.78% |
| May 8, 2024 | Mar 1, 2024 | -0.46 | — | — | — |
| Apr 4, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 5, 2024 | Chardan Capital | main | Buy | Buy |
| Apr 5, 2024 | Piper Sandler | down | Overweight | Neutral |
| Dec 14, 2023 | B of A Securities | down | Buy | Underperform |
| Aug 7, 2023 | Chardan Capital | reit | Buy | Buy |
| May 11, 2023 | Chardan Capital | main | Buy | Buy |
| Dec 7, 2022 | Chardan Capital | main | — | Buy |
About Achilles Therapeutics plc
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- Website
- achillestx.com
News
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca
- Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market
- Achilles Therapeutics Reports Third Quarter 2024 Financial Results
- Is Achilles Therapeutics (ACHL) Stock Outpacing Its Medical Peers This Year?
- Achilles Therapeutics Announces Strategic Update
- Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates
- Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
- Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
- Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Your note
Sign in to keep a note on ACHL — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Syncona Portfolio Ltd | 26.98% | 11,086,909 | 12.64M | Sep 29, 2024 |
| BML Capital Management, LLC | 9.98% | 4,100,002 | 4.67M | Sep 29, 2024 |
| Fcpm III Services B.v. | 5.82% | 2,390,050 | 2.72M | Sep 29, 2024 |
| Redmile Group, LLC | 3.91% | 1,608,089 | 1.83M | Sep 29, 2024 |
| Vestal Point Capital, LP | 3.65% | 1,500,000 | 1.71M | Sep 29, 2024 |
| Ikarian Capital, LLC | 3.51% | 1,443,181 | 1.65M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.05% | 21,590 | 24.61K | Oct 30, 2024 |
| Blackstone Alternative Multi-Strategy Fund | 0.00% | 100 | 113 | Sep 29, 2024 |